Cookies on VetMed Resource

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

VetMed Resource

Veterinary information to support practice, based on evidence and continuing education

Sign up to start receiving our Veterinary & Animal Sciences e-newsletter, book alerts and offers direct to your inbox.

Results per page:

Search results

Abstract

Currently, there is a growing interest in combining anticancer drugs with the aim to improve outcome in patients suffering from tumours and reduce the long-term toxicity associated with the current standard of treatment. In this study, we evaluated the possible role of deracoxib against the...

Author(s)
Bakırel, T.; Alkan, F. U.; Ustuner, O.; Çınar, S.; Anlas, C.; Sarı, A. B.
Publisher
Akadémiai Kiadó, Budapest, Hungary
Citation
Acta Veterinaria Hungarica, 2017, 65, 3, pp 366-381
Abstract

Objective - To determine whether exposure of canine osteosarcoma cells to deracoxib or piroxicam results in decreased viability, whether the cytotoxic effects of deracoxib and piroxicam involve induction of apoptosis, and whether deracoxib is a more potent inhibitor of osteosarcoma cell growth than ...

Author(s)
Royals, S. R.; Farese, J. P.; Milner, R. J.; Lee-Ambrose, L.; Gilder, J. van
Publisher
American Veterinary Medical Association, Schaumburg, USA
Citation
American Journal of Veterinary Research, 2005, 66, 11, pp 1961-1967
Abstract

The efficacy and safety of deracoxib administered at 1-2 mg/kg/day for 3 days was assessed for the control of postoperative pain and inflammation associated with dental surgery in dogs. Client-owned dogs scheduled for dental extractions were premedicated with butorphanol and randomly assigned to...

Author(s)
Bienhoff, S. E.; Smith, E. S.; Roycroft, L. M.; Roberts, E. S.; Baker, L. D.
Publisher
Hindawi Publishing Corporation, New York, USA
Citation
ISRN Veterinary Science, 2011, 2011, pp Article ID 593015
Abstract

Objective - To evaluate the efficacy of epidurally administered deracoxib to mediate the signs of a sodium urate crystal-induced stifle synovitis in dogs, and to compare the efficacy of epidural versus subcutaneously administered deracoxib. Study Design - Experimental, randomized, blinded,...

Author(s)
Karnik, P. S.; Johnston, S.; Ward, D.; Broadstone, R.; Inzana, K.
Publisher
Blackwell Publishing, Boston, USA
Citation
Veterinary Surgery, 2006, 35, 1, pp 34-42
Abstract

Background: Use of cyclo-oxygenase-2 specific nonsteroidal anti-inflammatory drugs such as deracoxib has been advocated because of their anti-inflammatory actions and apparently low incidence of gastrointestinal adverse effects. Hypothesis: Deracoxib will cause less endoscopically detectable...

Author(s)
Sennello, K. A.; Leib, M. S.
Publisher
American College of Veterinary Internal Medicine, Lakewood, USA
Citation
Journal of Veterinary Internal Medicine, 2006, 20, 6, pp 1291-1296
Abstract

Objective - To identify factors associated with gastrointestinal tract perforation in dogs being treated with a selective cyclooxygenase-2 (COX-2) inhibitor (deracoxib). Design - Retrospective study. Animals - 29 dogs. Procedure - The Novartis Animal Health pharmacovigilance database was searched...

Author(s)
Lascelles, B. D. X.; Blikslager, A. T.; Fox, S. M.; Reece, D.
Publisher
American Veterinary Medical Association, Schaumburg, USA
Citation
Journal of the American Veterinary Medical Association, 2005, 227, 7, pp 1112-1117
Abstract

Objective: To investigate the effectiveness and safety of deracoxib (Deramaxx®) administered at a dose of 1-2 mg/kg/day for 3 days for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Study Design: Prospective, randomized, blinded, placebo-controlled,...

Author(s)
Bienhoff, S. E.; Smith, E. S.; Roycroft, L. M.; Roberts, E. S.
Publisher
Wiley-Blackwell, Oxford, UK
Citation
Veterinary Surgery, 2012, 41, 3, pp 336-344
Abstract

The purpose of this study was to describe the clinical and gross pathological findings, treatment, and outcome in three dogs receiving deracoxib that developed proximal duodenal perforation and subsequent septic peritonitis. Clinical findings were acute vomiting and anorexia following initiation of ...

Author(s)
Case, J. B.; Fick, J. L.; Rooney, M. B.
Publisher
American Animal Hospital Association, Denver, USA
Citation
Journal of the American Animal Hospital Association, 2010, 46, 4, pp 255-258
Abstract

Canine hemangiosarcoma (HSA) is a highly malignant tumor for which standard chemotherapy has done little to substantially improve survival. Cyclooxygenase-2 (Cox-2) plays a role in the formation, growth, and metastasis of tumors and inhibitors have demonstrated therapeutic benefit with certain ...

Author(s)
Kahn, S. A.; Mullin, C. M.; Lorimier, L. P. de; Burgess, K. E.; Risbon, R. E.; Fred, R. M., III; Drobatz, K.; Clifford, C. A.
Publisher
Canadian Veterinary Medical Association, Ottawa, Canada
Citation
Canadian Veterinary Journal, 2013, 54, 3, pp 237-242
Abstract

During intense physical exercise, the cyclo-oxygenase-2 (COX-2) pathway is upregulated which contributes to soreness. The aim of this study was to determine if there was a clinical affect of deracoxib (COX-2 selective antagonist) on dogs engaged in intense rehabilitation following tibial plateau...

Author(s)
Gordon-Evans, W. J.; Dunning, D.; Johnson, A. L.; Knap, K. E.
Publisher
Schattauer GmbH, Stuttgart, Germany
Citation
Veterinary and Comparative Orthopaedics and Traumatology, 2010, 23, 5, pp 332-335

Refine Results

Sort Order
Author
Geographical Location
Item Type
Language
Organisms
Subject Topics